Finally, the recent genomic findings encourage investigation of the therapeutic potential of selective NR2A-targetting drugs (such as NR2A positive allosteric modulators) for schizophrenia, as part of the broader interest in glutamatergic treatments for the disorder [18, 29, 70, 71]. This evidence concerns the gene GRIN2A and schizophrenia.